Cargando…

The HDL particle composition determines its antitumor activity in pancreatic cancer

Despite enormous efforts to improve therapeutic options, pancreatic cancer remains a fatal disease and is expected to become the second leading cause of cancer-related deaths in the next decade. Previous research identified lipid metabolic pathways to be highly enriched in pancreatic ductal adenocar...

Descripción completa

Detalles Bibliográficos
Autores principales: Oberle, Raimund, Kührer, Kristina, Österreicher, Tamina, Weber, Florian, Steinbauer, Stefanie, Udonta, Florian, Wroblewski, Mark, Ben-Batalla, Isabel, Hassl, Ingrid, Körbelin, Jakob, Unseld, Matthias, Jauhiainen, Matti, Plochberger, Birgit, Röhrl, Clemens, Hengstschläger, Markus, Loges, Sonja, Stangl, Herbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Life Science Alliance LLC 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112193/
https://www.ncbi.nlm.nih.gov/pubmed/35577388
http://dx.doi.org/10.26508/lsa.202101317
_version_ 1784709370105298944
author Oberle, Raimund
Kührer, Kristina
Österreicher, Tamina
Weber, Florian
Steinbauer, Stefanie
Udonta, Florian
Wroblewski, Mark
Ben-Batalla, Isabel
Hassl, Ingrid
Körbelin, Jakob
Unseld, Matthias
Jauhiainen, Matti
Plochberger, Birgit
Röhrl, Clemens
Hengstschläger, Markus
Loges, Sonja
Stangl, Herbert
author_facet Oberle, Raimund
Kührer, Kristina
Österreicher, Tamina
Weber, Florian
Steinbauer, Stefanie
Udonta, Florian
Wroblewski, Mark
Ben-Batalla, Isabel
Hassl, Ingrid
Körbelin, Jakob
Unseld, Matthias
Jauhiainen, Matti
Plochberger, Birgit
Röhrl, Clemens
Hengstschläger, Markus
Loges, Sonja
Stangl, Herbert
author_sort Oberle, Raimund
collection PubMed
description Despite enormous efforts to improve therapeutic options, pancreatic cancer remains a fatal disease and is expected to become the second leading cause of cancer-related deaths in the next decade. Previous research identified lipid metabolic pathways to be highly enriched in pancreatic ductal adenocarcinoma (PDAC) cells. Thereby, cholesterol uptake and synthesis promotes growth advantage to and chemotherapy resistance for PDAC tumor cells. Here, we demonstrate that high-density lipoprotein (HDL)–mediated efficient cholesterol removal from cancer cells results in PDAC cell growth reduction and induction of apoptosis in vitro. This effect is driven by an HDL particle composition–dependent interaction with SR-B1 and ABCA1 on cancer cells. AAV-mediated overexpression of APOA1 and rHDL injections decreased PDAC tumor development in vivo. Interestingly, plasma samples from pancreatic-cancer patients displayed a significantly reduced APOA1-to-SAA1 ratio and a reduced cholesterol efflux capacity compared with healthy donors. We conclude that efficient, HDL-mediated cholesterol depletion represents an interesting strategy to interfere with the aggressive growth characteristics of PDAC.
format Online
Article
Text
id pubmed-9112193
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Life Science Alliance LLC
record_format MEDLINE/PubMed
spelling pubmed-91121932022-05-27 The HDL particle composition determines its antitumor activity in pancreatic cancer Oberle, Raimund Kührer, Kristina Österreicher, Tamina Weber, Florian Steinbauer, Stefanie Udonta, Florian Wroblewski, Mark Ben-Batalla, Isabel Hassl, Ingrid Körbelin, Jakob Unseld, Matthias Jauhiainen, Matti Plochberger, Birgit Röhrl, Clemens Hengstschläger, Markus Loges, Sonja Stangl, Herbert Life Sci Alliance Research Articles Despite enormous efforts to improve therapeutic options, pancreatic cancer remains a fatal disease and is expected to become the second leading cause of cancer-related deaths in the next decade. Previous research identified lipid metabolic pathways to be highly enriched in pancreatic ductal adenocarcinoma (PDAC) cells. Thereby, cholesterol uptake and synthesis promotes growth advantage to and chemotherapy resistance for PDAC tumor cells. Here, we demonstrate that high-density lipoprotein (HDL)–mediated efficient cholesterol removal from cancer cells results in PDAC cell growth reduction and induction of apoptosis in vitro. This effect is driven by an HDL particle composition–dependent interaction with SR-B1 and ABCA1 on cancer cells. AAV-mediated overexpression of APOA1 and rHDL injections decreased PDAC tumor development in vivo. Interestingly, plasma samples from pancreatic-cancer patients displayed a significantly reduced APOA1-to-SAA1 ratio and a reduced cholesterol efflux capacity compared with healthy donors. We conclude that efficient, HDL-mediated cholesterol depletion represents an interesting strategy to interfere with the aggressive growth characteristics of PDAC. Life Science Alliance LLC 2022-05-16 /pmc/articles/PMC9112193/ /pubmed/35577388 http://dx.doi.org/10.26508/lsa.202101317 Text en © 2022 Oberle et al. https://creativecommons.org/licenses/by/4.0/This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Articles
Oberle, Raimund
Kührer, Kristina
Österreicher, Tamina
Weber, Florian
Steinbauer, Stefanie
Udonta, Florian
Wroblewski, Mark
Ben-Batalla, Isabel
Hassl, Ingrid
Körbelin, Jakob
Unseld, Matthias
Jauhiainen, Matti
Plochberger, Birgit
Röhrl, Clemens
Hengstschläger, Markus
Loges, Sonja
Stangl, Herbert
The HDL particle composition determines its antitumor activity in pancreatic cancer
title The HDL particle composition determines its antitumor activity in pancreatic cancer
title_full The HDL particle composition determines its antitumor activity in pancreatic cancer
title_fullStr The HDL particle composition determines its antitumor activity in pancreatic cancer
title_full_unstemmed The HDL particle composition determines its antitumor activity in pancreatic cancer
title_short The HDL particle composition determines its antitumor activity in pancreatic cancer
title_sort hdl particle composition determines its antitumor activity in pancreatic cancer
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112193/
https://www.ncbi.nlm.nih.gov/pubmed/35577388
http://dx.doi.org/10.26508/lsa.202101317
work_keys_str_mv AT oberleraimund thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT kuhrerkristina thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT osterreichertamina thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT weberflorian thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT steinbauerstefanie thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT udontaflorian thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT wroblewskimark thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT benbatallaisabel thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT hasslingrid thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT korbelinjakob thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT unseldmatthias thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT jauhiainenmatti thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT plochbergerbirgit thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT rohrlclemens thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT hengstschlagermarkus thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT logessonja thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT stanglherbert thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT oberleraimund hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT kuhrerkristina hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT osterreichertamina hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT weberflorian hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT steinbauerstefanie hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT udontaflorian hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT wroblewskimark hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT benbatallaisabel hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT hasslingrid hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT korbelinjakob hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT unseldmatthias hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT jauhiainenmatti hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT plochbergerbirgit hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT rohrlclemens hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT hengstschlagermarkus hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT logessonja hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer
AT stanglherbert hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer